{"id":"mesoridazine-besylate","rwe":[],"tags":[],"safety":{"boxedWarnings":["Increased risk of extrapyramidal symptoms","Cardiovascular effects including QT prolongation"],"drugInteractions":["CYP450 inhibitors (e.g., fluoxetine, paroxetine)","Other drugs that prolong the QT interval (e.g., certain antiarrhythmics, antidepressants)"],"commonSideEffects":[],"contraindications":["Coma","Conduction disorder of the heart","Congenital long QT syndrome","Epilepsy","Granulocytopenic disorder","Hyperkalemia","Hypokalemia","Neuroleptic malignant syndrome","Orthostatic hypotension","Predisposed to Torsades de Pointes Cardiac Arrhythmias","Prolonged QT interval","Stupor","Tardive dyskinesia"],"specialPopulations":{"Elderly":"Use with caution due to increased risk of side effects","Pregnancy":"Category C; use only if the potential benefit justifies the potential risk to the fetus","Renal impairment":"Adjust dosage based on renal function","Hepatic impairment":"Use with caution; monitor closely"}},"trials":[],"_chembl":{"chemblId":"CHEMBL1201052","moleculeType":"Small molecule","molecularWeight":"544.76"},"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=MESORIDAZINE BESYLATE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:52:32.340371+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:52:44.728498+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=MESORIDAZINE BESYLATE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:52:45.491873+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Serotonin 2a (5-HT2a) receptor antagonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:52:46.069337+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201052/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:52:45.974891+00:00"}},"offLabel":[],"timeline":[{"date":"1960s","type":"Approval","milestone":"First approved for use","regulator":"Various"},{"date":"2000s","type":"Withdrawal","milestone":"Withdrawn from the market in many countries","regulator":"Various"}],"_dailymed":null,"aiSummary":"Mesoridazine besylate is an antipsychotic medication that was previously used for the treatment of schizophrenia and other psychotic disorders. It works by blocking dopamine receptors in the brain, which helps to reduce symptoms such as hallucinations and delusions. However, due to its significant side effect profile, including extrapyramidal symptoms and cardiovascular issues, it is no longer widely prescribed. The drug has been withdrawn from the market in many countries, and there is no current FDA-approved label. Despite this, mesoridazine besylate remains a topic of interest in historical and comparative studies of antipsychotic medications.","ecosystem":[],"mechanism":{"target":"5-hydroxytryptamine receptor 6, D(4) dopamine receptor, 5-hydroxytryptamine receptor 1A","novelty":"Not considered novel; it is an older antipsychotic","modality":"Oral","drugClass":"Typical antipsychotic","explanation":"","oneSentence":"","technicalDetail":"Mesoridazine binds to dopamine D2 receptors with high affinity, leading to a reduction in dopaminergic neurotransmission."},"_scrapedAt":"2026-03-28T00:42:52.077Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"commercial":{"yoyGrowth":0,"launchDate":"N/A","annualCostUS":0,"currentRevenue":0,"patientPopulation":"Not applicable (withdrawn from market)","peakSalesEstimate":0},"references":[],"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:52:47.908545+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":["Haloperidol","Fluphenazine","Chlorpromazine","Thioridazine"],"indications":{"approved":[{"name":"Schizophrenia","diseaseId":"schizophrenia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":["Schizophrenia","Psychotic disorders"],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT01231074","phase":"PHASE1","title":"Reducing Antipsychotic-Induced Weight Gain in Children With Metformin","status":"COMPLETED","sponsor":"Nationwide Children's Hospital","startDate":"2010-02","conditions":"Obesity, Weight Gain, Psychotropic Induced Weight Gain","enrollment":96},{"nctId":"NCT02582736","phase":"","title":"Antipsychotics and Risk of Hyperglycemic Emergencies","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2012-04","conditions":"Psychotic Disorders, Schizophrenia, Schizoaffective Disorder","enrollment":725489}],"_emaApprovals":[],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"chemblId":"CHEMBL1201052"},"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":6,"therapeuticAreas":["Neuroscience"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"approved","brandName":"MESORIDAZINE BESYLATE","genericName":"MESORIDAZINE BESYLATE","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"1970","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:52:47.908545+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}